Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Deffered Revenue (2017 - 2025)

Protagonist Therapeutics' Non-Current Deffered Revenue history spans 6 years, with the latest figure at $2.8 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 83.11% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $2.8 million, down 83.11%, while the annual FY2024 figure was $11.7 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $2.8 million at Protagonist Therapeutics, down from $5.4 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $28.9 million in Q1 2024 and bottomed at $2.8 million in Q3 2025.